Febrile neutropenia
| Autor: | J, Klastersky |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Clinical Trials as Topic
Cancer Research Neutropenia Fever Bacteremia Antineoplastic Agents Bacterial Infections Ceftazidime Fever of Unknown Origin Mycoses Oncology Vancomycin Virus Diseases Amphotericin B Neoplasms Humans Drug Therapy Combination Gram-Negative Bacterial Infections Amikacin Gram-Positive Bacterial Infections |
| Zdroj: | Supportive Care in Cancer. 1:233-239 |
| ISSN: | 1433-7339 0941-4355 |
| DOI: | 10.1007/bf00366041 |
| Popis: | Severe neutropenia and its related infectious complications remain a permanent threat for patients receiving intensive chemotherapy, especially in the context of bone marrow transplantation. Chemoprophylaxis and use of colony-stimulating factors have altered the severity of the clinical picture in a favorable direction: neutropenia can be shortened, and gram-negative infection can be made less frequent; neither can be yet abolished. Early therapy, eg, empiric combination treatment, remains the cornerstone of our approach to febrile neutropenia; the actual choice of agents is probably less important and should be guided by local epidemiologic conditions. The concepts of empiric therapy also starts to be more widely accepted for the control of fungal and viral infections. Finally, it is fair to recognize that, at the other end of the spectrum of febrile neutropenia, conventional chemotherapy that results in only moderate and short neutropenia can usually be managed without much problem, namely with broad-spectrum monotherapy. Other possible simplified approaches should be investigated under controlled conditions and in patients selected on the basis of favorable prognostic factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink